Tetrabenazine

Expert Opinion on Pharmacotherapy
Alfonso Fasano, Anna Rita Bentivoglio

Abstract

Tetrabenazine (TBZ) depletes presynaptic dopamine in the CNS. It has been found to be beneficial in hyperkinetic movement disorders without carrying the extrapyramidal side effects that are characteristic of neuroleptics. To summarize current knowledge on the use of TBZ and draw conclusions about its efficacy and safety. PubMed literature searches using the term 'tetrabenazine' were carried out for the period prior to May 2009. Additional relevant studies referenced by these publications were included. Both short- and long-term studies have consistently yielded favorable results for the use of TBZ in the treatment of hyperkinetic movement in terms of efficacy and safety. TBZ is most effective in reducing chorea (including Huntington's disease associated chorea), tic associated with Tourette's syndrome and tardive dyskinesias. Furthermore, TBZ might also have potential for use in other hyperkinetic disorders (e.g., myoclonus and dystonia), for which future clinical trials are needed.

References

Jun 1, 1975·The Australian and New Zealand Journal of Psychiatry·D P LeonardS Taryan
Mar 1, 1979·The American Journal of Psychiatry·E D CaineM H Ebert
Jun 30, 1979·The Medical Journal of Australia·D Kingston
Oct 1, 1978·Annals of Neurology·K Kondo, T Kabasawa
Oct 1, 1977·Neurology·M M Hoehn, M Cherington
Nov 1, 1977·British Journal of Pharmacology·D R Tomlinson
Jan 1, 1992·Movement Disorders : Official Journal of the Movement Disorder Society·M Stacy, J Jankovic
Aug 1, 1987·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·J Jankovic, H Rohaidy
Feb 1, 1988·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·M W WatsonF Jamali
Jun 1, 1987·Journal of Pharmaceutical Sciences·R Mehvar, F Jamali
Oct 1, 1986·Archives of Neurology·J Jankovic, R Pardo
Feb 1, 1985·Annals of Neurology·R E BurkeS Fahn
Jan 1, 1968·Acta Neurologica Scandinavica·H Pakkenberg
Dec 1, 1974·Brain : a Journal of Neurology·C D Marsden, M J Harrison
Jul 1, 1972·Archives of General Psychiatry·H KazamatsuriJ O Cole
Aug 1, 1984·Journal of Neurology, Neurosurgery, and Psychiatry·N Quinn, C D Marsden
Jan 1, 1984·Current Medical Research and Opinion·J DerooverP Smets
Aug 1, 1981·Neurology·S W Asher, M J Aminoff
Jan 1, 1982·Acta Neurologica Scandinavica·R A RoosE A van der Velde
Nov 1, 1984·Journal of Neurology, Neurosurgery, and Psychiatry·C D MarsdenN Quinn
Sep 1, 1982·Annals of Neurology·I S LoginR M MacLeod
Mar 1, 1994·Brain Research. Molecular Brain Research·A M GonzalezG R Uhl
May 14, 1996·Proceedings of the National Academy of Sciences of the United States of America·J D EricksonE Weihe
Jan 1, 1996·Movement Disorders : Official Journal of the Movement Disorder Society·M OssemannC Laterre
Mar 1, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·G M Petzinger, S B Bressman
Jul 1, 1997·Journal of Neurology, Neurosurgery, and Psychiatry·J P van VugtR A Roos
Sep 26, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·E Storey, J Lloyd
Jun 3, 1998·Intensive Care Medicine·E StevensN Jaspar
May 29, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·A BerardelliR A Roos
Oct 23, 2001·Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie·T SatouS Hashimoto
Nov 2, 2002·The British Journal of Psychiatry : the Journal of Mental Science·Jennifer HallidayRobin McCreadie
Nov 22, 2002·Lancet·James F Leckman
Dec 7, 2002·Clinical Neuropharmacology·William G OndoJoseph Jankovic
Jun 5, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Anjan Chatterjee, Steven J Frucht
Oct 29, 2003·Neurology·N MahantUNKNOWN Huntington Study Group

❮ Previous
Next ❯

Citations

Mar 3, 2011·Current Treatment Options in Neurology·Pratibha G AiaStewart A Factor
Oct 30, 2013·Journal of Neurology, Neurosurgery, and Psychiatry·Alfonso FasanoAnthony E Lang
Jul 30, 2014·Journal of Psychiatric Research·Seiya MiyamotoW Wolfgang Fleischhacker
Oct 22, 2011·Expert Review of Neurotherapeutics·Joseph Jankovic, Kathleen Clarence-Smith
Jul 15, 2015·Expert Opinion on Emerging Drugs·Jonathan Tomas Lockwood, Gary Remington
May 18, 2012·Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy·Ana C P OsórioRicardo Q Aucélio
Jan 29, 2011·Annals of the New York Academy of Sciences·Lee E Eiden, Eberhard Weihe
Aug 28, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·Joshua ListerGary Remington
Jul 1, 2015·CNS Neuroscience & Therapeutics·Sheng ChenWei-Dong Le
Nov 8, 2016·Expert Opinion on Pharmacotherapy·Joseph Jankovic
Apr 14, 2011·The Annals of Pharmacotherapy·Jonathan G Leung, Ericka L Breden
Apr 11, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Alfonso FasanoNardo Nardocci
Dec 5, 2014·Pharmacotherapy·Antonino NaroRocco Salvatore Calabrò
Dec 27, 2011·Journal of Clinical Psychopharmacology·Gary RemingtonNaima Javaid
Aug 13, 2017·Neurology·Ariel Levy, Alfonso Fasano
Nov 27, 2010·Cardiovascular Therapeutics·David S Goldstein
Jan 3, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Raja MehannaJoseph Jankovic
Aug 10, 2010·ACS Medicinal Chemistry Letters·Qian-Sheng YuNigel H Greig

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here